SPRY
NASDAQ
$6.36
ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $26.75 (+320.60%)
Market Cap
$750M
FCF 5Y CAGR
+36.73%
Free Cash Flow Yield
-23.38%
Beta (5Y)
1.16
Price Chart
Valuation
Market Cap$750M
P/S7.57
P/B12.33
Profitability
Total Revenue (TTM)$99M
Gross Profit (TTM)$59M
EBITDA-$201M
Profit Margin-200%
Operating Margin-265.2%
EPS-$2.00
Financial Health
Debt-to-Equity157.4%
Free Cash Flow Yield-23.38%
Growth & Risk
FCF 5Y CAGR+36.73%
Beta (5Y)1.16
Sharpe Ratio-1.17